{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:37:11Z","timestamp":1793831831009,"version":"4.6.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.canlet.2024.216933","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T01:58:04Z","timestamp":1714787884000},"page":"216933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia"],"prefix":"10.1016","volume":"592","author":[{"given":"Yuxin","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3889-4989","authenticated-orcid":false,"given":"Lilan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-1786","authenticated-orcid":false,"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0982-0382","authenticated-orcid":false,"given":"Fuling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216933_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102993","article-title":"Targeting acute myeloid leukemia stem cells: current therapies in development and potential strategies with new dimensions","volume":"152","author":"Tan","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2024.216933_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216933_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2021.1875814","article-title":"A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'","volume":"14","author":"Bazinet","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.canlet.2024.216933_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2024.216933_bib5","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.canlet.2024.216933_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114348","article-title":"Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors","volume":"183","author":"Marensi","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216933_bib7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00277-014-2072-6","article-title":"Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis","volume":"93","author":"Port","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2024.216933_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41375-021-01462-4","article-title":"The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML","volume":"36","author":"Charlet","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216933_bib9","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216933_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216933_bib11","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2017.22","article-title":"Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216933_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216933_bib13","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216933_bib14","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41375-020-0872-3","article-title":"Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years","volume":"34","author":"Eisfeld","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216933_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216933_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"Dohner","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216933_bib17","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-23-0954","article-title":"Improved posttransplant outcomes in recent years for AML patients with FLT3-ITD and wild-type NPM1: a report from the EBMT acute leukemia working party","volume":"29","author":"Bazarbachi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216933_bib18","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.26892","article-title":"Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia","volume":"98","author":"Lo","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2024.216933_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12185-023-03567-1","article-title":"Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study","volume":"118","author":"Miyashita","year":"2023","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.canlet.2024.216933_bib20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216933_bib21","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216933_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.12599","article-title":"Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase","volume":"164","author":"Yang","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216933_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","article-title":"FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Wu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216933_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216933_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216933_bib26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216933_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.872729","article-title":"Overcoming cancer drug resistance utilizing PROTAC Technology","volume":"10","author":"Burke","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2024.216933_bib28","doi-asserted-by":"crossref","first-page":"16428","DOI":"10.1021\/jacs.8b10320","article-title":"Enhancing antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion","volume":"140","author":"Burslem","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2024.216933_bib29","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216933_bib30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","article-title":"ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia","volume":"33","author":"Maes","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216933_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/cmi.2012.6","article-title":"Engineering humanized mice for improved hematopoietic reconstitution","volume":"9","author":"Drake","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2024.216933_bib32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/bmt.2015.290","article-title":"The gender gap: discrepant human T-cell reconstitution after cord blood stem cell transplantation in humanized female and male mice","volume":"51","author":"Volk","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2024.216933_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104877","article-title":"Nicotinamide mononucleotide impacts HIV-1 infection by modulating immune activation in T lymphocytes and humanized mice","volume":"98","author":"Mo","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2024.216933_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112991","article-title":"How ITD insertion sites orchestrate the biology and disease of FLT3-ITD-mutated acute myeloid leukemia","volume":"15","author":"Haage","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216933_bib35","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-Like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.canlet.2024.216933_bib36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2024.216933_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/leu.2017.257","article-title":"Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia","volume":"32","author":"Reiter","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216933_bib38","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1182\/blood-2017-12-819508","article-title":"RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML","volume":"131","author":"Cucchi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216933_bib39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2015.06.016","article-title":"Genetic determinants of platelet large-cell ratio, immature platelet fraction, and other platelet-related phenotypes","volume":"136","author":"Pujol-Moix","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.canlet.2024.216933_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.advms.2020.05.002","article-title":"Characteristics of platelet indices and their prognostic significance in selected medical condition - a systematic review","volume":"65","author":"Pogorzelska","year":"2020","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.canlet.2024.216933_bib41","article-title":"Prognostic impact of platelet-large cell ratio in myelodysplastic syndromes","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216933_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106189","article-title":"Expression of platelet parameters and platelet membrane glycoproteins in childhood Burkitt lymphoma","volume":"84","author":"Asare","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2024.216933_bib43","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/j.1538-7836.2011.04506.x","article-title":"Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia","volume":"9","author":"Psaila","year":"2011","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.canlet.2024.216933_bib44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.canlet.2024.216933_bib45","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216933_bib46","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216933_bib47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2024.216933_bib48","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216933_bib49","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216933_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-020-00973-4","article-title":"Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia","volume":"13","author":"Brinton","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216933_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-023-01411-x","article-title":"Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting","volume":"16","author":"DiNardo","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216933_bib52","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216933_bib53","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood.2021011582","article-title":"Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression","volume":"138","author":"Lv","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216933_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025351","article-title":"Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells","volume":"6","author":"Weisberg","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216933_bib55","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2012-01-403493","article-title":"Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3\/ITD leukemia","volume":"120","author":"Williams","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216933_bib56","first-page":"587","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Dev. Reprod. Biol."},{"key":"10.1016\/j.canlet.2024.216933_bib57","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2024.216933_bib58","doi-asserted-by":"crossref","first-page":"W43","DOI":"10.1093\/nar\/gkz337","article-title":"DrugComb: an integrative cancer drug combination data portal","volume":"47","author":"Zagidullin","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2024.216933_bib59","doi-asserted-by":"crossref","first-page":"W174","DOI":"10.1093\/nar\/gkab438","article-title":"DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal","volume":"49","author":"Zheng","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2024.216933_bib60","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2024.216933_bib61","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-020-04186-0","article-title":"Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia","volume":"99","author":"Megias-Vericat","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2024.216933_bib62","series-title":"VENCLEXTA\u00ae (Venetoclax)","year":"2018"},{"key":"10.1016\/j.canlet.2024.216933_bib63","series-title":"XOSPATA\u00ae (Gilteritinib)","year":"2018"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T21:11:06Z","timestamp":1716412266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524003264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":63,"alternative-id":["S0304383524003264"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216933","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216933"}}